Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke
Conclusions
Co-therapy with ASA plus PPI appears to be cost-effective compared with ASA monotherapy. The addition of PPI also appeared to prolong the duration of ASA therapy, thereby reducing the risk of ischemic stroke.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Aspirin | Bleeding | Dyspepsia | Gastroenterology | Health Management | Hemorrhagic Stroke | Ischemic Stroke | Proton Pump Inhibitors PPIs | Stroke